1. The transport of 6-thioguanine and 6-mercaptopurine has been studied with isolated jejunal loops of mouse small intestine. H.p.1.c. was used to identify and quantify the thiopurines and their metabolites in the serosal secretions.
INTRODUCTION
Previous work [l] has shown that in the rat naturally occurring purines are extensively metabolized to uric acid during transport from the lumen of the rat small intestine to the serosal secretions. The intestinal lumen has ample sources of exogenous and endogenous purines [l, 21, but there is no evidence that they are accumulated by the intestinal mucosa. After absorption from the lumen, adenine and guanine, as well as their metabolites hypoxanthine and xanthine, are largely converted to uric acid which is released in the serosal secretions [l] . We have also shown that uric acid itself is transported by mouse small intestine [3] as it is in the rat [4].
6-Thioguanine and 6-mercaptopurine are chemotherapeutic antimetabolites which are commonly administered to patients by mouth [5] . Both compounds are absorbed from the gastrointestinal tract, but little information is available on the absorptive process or the way that absorption is influenced by intestinal metabolism of the drugs. 6-Mercaptopurine is known to be converted to 6-thiourie acid by xanthine oxidase (EC 1.2.3.2) [5, 6] , but 6-thioguanine is not thought to be metabolized by this pathway [5, 7] .
The xanthine oxidase inhibitor allopurinol is often administered with 6-mercaptopurine in order to inhibit catabolism of the drug [5, 61. Allopurinol is transported by the intestine and is extensively metabolized to oxypurino1 in the rat [4] . However, we have reported that in the mouse conversion of allopurinol to oxypurinol is negligible [3] .
In this paper we report an investigation of the transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine, together with the effects of xanthine oxidase inhibitors on these processes.
METHODS

Animals
Adult male Balb/c mice, which were bred in the Department of Biology, were fed on a standard laboratory diet (Oxoid modified BIO 41B diet) with free access to water in conditions of controlled temperature and light.
Perfusion technique
The technique used for perfusion in vitro was as described previously [3] and is similar to that of Morton & Hanson [8] , with a recirculated luminal perfusate segmented with bubbles of O,+CO, (95:5, v/v) by the method of Fisher & Gardner [9] . The mice were anaesthetized (intramuscularly) with sodium pentobarbitone BP (0.14 mg/g; May and Baker Ltd). A 16 cm segment of the intestine (immediately distal to the ligament of Treitz) was perfused with a modified bicarbonate-Ringer solution [ 101 containing 28 mmol/l D-glucose and equilibrated with O,/CO, (95 : 5, v/v) at 37°C. Perfusate was pumped through the lumen at 4 ml/min mixed 2:l with O,/CO,. Once this flow was established, the segment was transferred to a water-jacketed vessel maintained at 37°C where the intestine was supported in liquid paraffin (sp. gravity 0.85-0.86) ill].
The perfusate (100 ml) from one reservoir was recirculated through the lumen for 15 min, after which 100 ml of a second perfusate previously equilibrated with 0 2 / C 0 2 in a second reservoir was recirculated for a further 85 min. The second perfusate was identical with the first except for the addition of the drugs or inhibitors to be studied. The perfusion time was measured from the point at which the segment was isolated from the animal.
The serosal secretions, which appeared as droplets on the surface of the intestinal segment, fell to the bottom of the liquid paraffin supporting the intestine and were collected through a tap into calibrated microcentrifuge tubes. The serosal secretion was first collected at 15 min before the switch in perfusate, next at 20 min and then at 10 min intervals for a further 80 min. The volume of each sample of serosal secretion was measured after centrifugation to separate it from the small amount of liquid paraffin collected with each sample. At the end of the perfusion the intestinal segment was freed of any mesentery, cut open, blotted and dried to constant weight in an air oven at 90°C.
The viability of the isolated loops was assessed by the constancy of serosal fluid appearance and by the capacity of the intestine to transport glucose from the lumen to the serosal secretions (see control points in Fig. 10 ). After the perfusion had been established for 30 min the mean ratio of serosal to luminal glucose concentrations in the control was 3.65f0.08 ( m e a n f~~~) .
Checks were made for gross leaks, and the perfusion was abandoned in the rare cases where they occurred. The volume of the first sample was variable, but over the experimental period from 20 to 100 min the rate of fluid transport was linear (see control curve in Fig. 9 ). Glucose was measured with a commercial kit (Boehringer, London).
Chromatography
Samples of the luminal perfusate and the serosal secretions were analysed by h.p. and the quantities of purines in the samples were determined by peak height measurement with reference to external standards [ 1 11 . The chromatograms obtained with mixtures of 6-thioguanine (Fig. l a ) or 6-mercaptopurine (Fig. l b ) with uracil, uric acid, 6-thiouric acid, 6-thioxanthine, allopurino1 and oxypurinol at both 254 and 310 nm are shown in Fig. 1 . Each of the constituents of the two mixtures in Fig.  1 were present at the same concentration (25 pmol/l).
Identification of compounds in the serosal secretions. With the exception of 6-thiouric acid, the peaks obtained in chromatograms of the serosal secretions were identified by co-chromatography with reference compounds. The absorbance ratios at different wavelengths and U.V. scans of the peaks on the serosal secretion chromatograms were also checked against those of reference compounds. 6-Thiouric acid was not available commercially but the peak marked as 6-thiouric acid in Fig. 1 was identified in three ways. The peak appeared when 6-thioxanthine or 6-mercaptopurine were treated with xanthine oxidase; it also appeared when 6-thioguanine was treated with guanine deaminase and xanthine oxidase and if a serosal sample showing the peak was treated with uricase the peak was reduced in height by 41%. In addition, as shown by the U.V. scans in Fig. 4 , the peak we identified as 6-thiouric acid has the absorption characteristics of a thiopurine.
Materials
All chemicals and reagents were of the highest purity available. 6-Thioguanine, 6-mercaptopurine, uracil, uric acid, allopurinol, oxypurinol and 6-thioxanthine were obtained from Sigma Chemical Company Ltd, Poole, 
Expression of results
The compounds in the serosal secretions are described in terms of their concentrations and as rates of appearance on the serosal side of the preparation, per g dry weight (nmol min-' g-' dry wt.) of intestine, as determined by regression analysis. All values are reported as means zk SEM with n shown in parentheses. Statistical comparisons were made by analysis of variance except for the cumulative plots where co-variance analysis was used. Regression lines and the associated standard errors were calculated from the individual values in the cumulative plots.
RESULTS
Transport of 6-thioguanine
start of the perfusion, and Fig. 2 shows the appearance with time of 6-thioguanine and the compound identified as 6-thiouric acid. When the luminal concentration of 6-thioguanine was 0.5 or 1.0 mmol/l, both the unmetabolized drug and the metabolite began to appear in the 30 min serosal sample and the concentration of both compounds reached approximately the same level by the end of the perfusion. At a 6-thioguanine concentration of 0.1 mmol/l, on the other hand, less than 15% of the serosal thiopurine was in the form of unmetabolized drug.
Since the volume of each serosal sample is measured the cumulative appearance of compounds in the serosal secretions can be calculated. Fig. 3 shows the cumulative appearance of both 6-thioguanine and 6-thiouric acid at the three luminal drug concentrations. The regression lines in Fig. 3 were calculated over the 50-100 min time period as shown by the length of the lines and they indicate that the serosal appearance of the drug (Fig. 3a) and its metabolite ( with 6-thioguanine co-eluted with the product formed when 6-thioxanthine was incubated with xanthine oxidase and therefore was identified as 6-thiouric acid. Since 6-thioguanine was not thought to be metabolized by the xanthine oxidase pathway [5, 71, we incubated the drug with guanine deaminase and xanthine oxidase. The resulting product also co-eluted with the compound in the serosal secretion that we had identified as 6-thiouric acid. Fig.  4 shows U.V. scans for 6-thioguanine, 6-thioxanathine, uric acid and the compound that has been identified as 6-thiouric acid. At the shorter wavelengths the absorbance spectrum of 6-thiouric acid is similar to that of other purines, but it also has an absorbance maximum in the 340 nm region which is characteristic of the thiopurines, 6-thioguanine and 6-thioxanthine.
Effect of oxypurinol on 6-thioguanine transport and metabolism
Oxypurinol has been shown to inhibit xanthine oxidase [12, 131 , and when it was present in the luminal perfusate at a concentration of 0.3 mmol/l no measurable 6-thiouric 
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shows that a small amount of 6-thioxanthine appeared in the serosal secretions [final concentration 0.015 fO.OOl(n= 3) mmol/l] as would be expected if the 6-thioguanine was being converted to 6-thiouric acid by the action of guanine deaminase and xanthine oxidase. However, Fig. 5 (a) also indicates that the inhibition of 6-thioguanine catabolism by oxypurinol resulted in a reduction (P<O.OOl) in the serosal appearance of the drug rather than an increase. The final concentration of the drug in the serosal secretions was reduced from 0.127f0.019 (n=3) to 0.060+0.009 (n=3) mmol/l in the presence of oxypurinol ( P < 0.05) and the cumulative rate of appearance was inhibited by 54%. The inhibition of serosal thiopurine appearance by oxypurinol is even more striking when the total of 6-thioguanine plus 6-thiouric acid in the serosal secretions in the absence of inhibitor is compared with 6-thioguanine plus 6-thioxanthine in the presence of oxypurinol (Fig. 5b) , since the rate of appearance of thiol compounds in the serosal secretions is reduced by 73%. There was no evidence that the rate of water transport was affected by the presence of 6-thioguanine or oxypurinol in the lumen.
Transport of 6mercaptopurine
The transport of 6-mercaptopurine was examined in two groups of perfusions with luminal drug concentra- the lumen only 10% was unmetabolized. From Fig. 6 it can be seen that the time course of serosal appearance was similar for 6-mercaptopurine and 6-thiouric acid. reaching a steady concentration about 50 min after the drug was introduced into the lumen. When the volumes of the serosal secretions are taken into account the cumulative rate of serosal appearance can be calculated. Fig. 7 shows that both the 6-thiouric acid and 6-mercaptopurine appeared in the serosal secretions at a constant rate after the drug had been present in the lumen for 20-30 min, despite the substantial inhibition of water transport by 6-mercaptopurine (see Fig. 9 below). 
Influence of xanthine oxidase inhibitors on 6-mercaptopurine transport
When the xanthine oxidase inhibitor oxypurinol at 0.3 mmol/l was added to the luminal perfusate together with 6-mercaptopurine, no 6-thiouric acid was found in the serosal secretions. Fig. 8 shows that the oxypurinol increased the rate of appearance of 6-mercaptopurine in the serosal secretions ( P < 0.001), although the rate was not equal to the rate for 6-mercaptopurine plus 6-thiouric acid (P<O.OOl).
( P < 0.01). With 0.1 mmol/l 6-mercaptopurine and d opurinol in the lumen the rate at which the drug appeared in the serosal secretions was not significantly below the rate of appearance of 6-thiouric acid plus unmetabolized drug. No 6-thioxanthine was found when the intestine was
The addition of 0.3 mmol/l allopurinol also prevented the formation of 6-thiouric acid, and as Inhibition of glucose and water transport by 6-mercaptopurine
The water transport in a group of control perfusions is shown in Fig. 9 . The rate remained constant from 20 to 100 min at 0.513f0.018 ( n = 5 ) ml min-' g-' dry wt. When 6-mercaptopurine was present in the lumen at a concentration of 0.1 mmol/l, the rate was again constant but it was reduced by 30%. This inhibition of water transport (P<O.OOl compared with the control) was not increased when the luminal6-mercaptopurine concentration was 1 mmol/l, nor did it change significantly when metabolism of the drug was inhibited by allopurinol or Since water transport in intestinal loops is dependent on glucose transport [8] , it was of interest to see how the serosal appearance of D-glucose was influenced by 6-mer0XypuMol. captopurine. Fig. 10 shows the glucose concentrations in the serosal secretions of the five control perfusions and five with 0.1 mmol/l 6-mercaptopurine in the lumen. In both cases the serosal glucose concentration was maximal after perfusion for 30 min and remained virtually constant for the next 60 min. The mean glucose concentration in the controls from 30 to 90 min was 98.6 f 0.4 mmol/l and this was reduced to 87.3k0.8 mmol/l by the drug (P<O.OOl). When the rates of water transport were taken into account the drug was found to inhibit the rate of glucose transport by 39% from 50.6 f 3.2 ( n = 5) pnol min-1g-Ldrywt.inthecontrolto31.0f 1.2(n=5)pmol min-' g-l dry wt. in the presence of 0.1 mmol/l 6-mercaptopurine (P<O.OOl). The rate of glucose transport in the presence of the drug plus allopurinol or oxypurinol was not significantly different from that in the presence of the drug alone.
Luminal disappearance of thiopurine drugs
The technique used for the transport studies reported in this paper is not suitable for a study of luminal disappearance because a relatively large volume of luminal perfusate is recirculated through the isolated loops in order to minimize changes in luminal D-glucose. As a consequence it was not possible to make an accurate estimate of the disappearance of either of the thiopurine drugs from the lumen. When the loops were perfused with 6-thioguanine or 6-mercaptopurine at 1 mmol/l the final luminal concentration appeared to be lower at 0.86 f 0.07 ( n = 3) mmol/l and 0.95 f 0.03 (n = 5) mmol/l, respectively, but these values are not significantly below the initial concentrations ( P > 0.1). However, it is interesting to note that when the loops are perfused with 0.3 mmol/l oxypurinol in addition to either 6-thioguanine or 6-mercaptopurine at 1 mmol/l, the final luminal concentrations were 1 .OO * 0.05 (n = 3) mmol/l and 1.03 k 0.02 ( ) I = 6 ) mmol/l, respectively. This suggests that the inhibitor may reduce luminal uptake as well as inhibiting metabolism.
DISCUSSION
The results reported in this paper show the importance of the metabolism of the thiopurine drugs during their transmural transport by mouse small intestine. In the rat, intestinal metabolism has been found to account for a sizeable proportion of the glucose [ 14, 151, glutamine [ 161 and natural purines [ l ] absorbed by the small intestine. Our data add a further category of organic molecule to those previously shown to be metabolized to a significant extent during mammalian intestinal transport. We have found that transport and metabolism of the thiopurine drugs in the mouse resembles that of the natural purines in the rat [ 11. Neither 6-thioguanine nor 6-mercaptopurine is actively transported by mouse intestine and both of the drugs are extensively metabolized to a compound we have identified as 6-thiouric acid. Previous work [17] suggested that uric acid was formed from purines in the intestine. Parsons & Shaw [ l ] demonstrated with isolated loops of rat intestine that luminal guanine, hypoxanthine and xanthine did not appear in the serosal secretions and that all three compounds were extensively metabolized in the intestine as shown by the increase in the serosal appearance of uric acid. Hypoxanthine and xanthine are converted directly to uric acid by xanthine oxidase and guanine deaminase converts guanine to xanthine [ 181. In contrast, luminal adenine gave rise to adenine in the serosal secretions of rat intestine as well as causing an increase in the serosal appearance of uric acid [l] ; this may be a consequence of the necessity to convert adenine to the nucleotide form (adenosine 5'-phosphate) before it can be metabolized to uric acid [ 181, or it may simply be an indication of a low level of adenine deaminase in the intestine. The results presented in Fig. 3 and Fig. 6 indicate that the transport of 6-thioguanine and 6-mercaptopurine in mouse intestine resembles that of adenine in the rat more closely than that of guanine, since even at luminal concentrations of 0.1 mmol/l some of the unmetabolized drug appeared in the serosal secretions.
On the other hand, the metabolism of the two thiopurines in the mouse appears to follow that of guanine and hypoxanthine in the rat. Fig. 11 shows the metabolic steps responsible for the conversion of the two drugs to 6-thiouric acid. We have observed the formation of peak which had a spectrum and retention time identical with that of the 6-thiouric acid produced from the drugs by enzymes obtained commercially. The conversion of 6-thioguanine to 6-thiouric acid was unexpected [5] , but the pathway shown in Fig. 11 was confirmed by the appearance of 6-thioxanthine in the serosal secretions of mouse loops perfused with 6-thioguanine plus oxypurino1 to inhibit the xanthine oxidase.
In view of the rapid'degradation of 6-thioguanine in mouse intestine, it is reasonable to expect that the addition of oxypurinol might give higher rates of serosal appearance of the drug. However, Fig. 5 shows that 6-thioguanine appears in the serosal secretions at a reduced rate in the presence of the xanthme oxidase inhibitor despite the fact that no 6-thiouric acid is formed. We have reported a similar inhibition by oxypurinol of the transport of uric acid from the lumen to the serosal secretions in the mouse osal appearance of 6-thioguanine indicate that the delivery of the drug from the lumen to the blood is unlikely to be improved by inhibiting its metabolism. The conversion of 6-mercaptopurine to 6-thiouric acid in the mouse (Fig. 6 and Fig. 7) was expected on the basis of previous reports [5-71 with other species. With 0.1 mmol/l6-mercaptopurine present in the lumen more than 90% of serosal thiopurine was 6-thiouric acid. The inclusion of either xanthine oxidase inhibitor increased the rate at which unmetabolized 6-mercaptopurine appeared in the serosal secretions, but it is clear from Fig. 8 that the rates obtained with allopurinol are higher ( P < 0.001) than those obtained with the same concentration of oxypurinol, particularly when the luminal drug concentration was 0.1 mmol/l. This is consistent with our observation [3] that the transport of uric acid from the lumen to the serosal secretions in the mouse is inhibited by oxypurinol but not allopurinol. The results reported in Fig. 8 confirm that the practice -of administering 6-mercaptopurine together with allopurinol will give the most effective delivery of the drug from the lumen to the blood. However, it should be noted that in our experiments the absence of an inhibition of the serosal secretion of thiopurines by dopurinol is likely to be due to the fact that allopurinol is not converted to oxypurinol in the mouse small intestine [3] , as it is in other species [4, 12, 131.
From a comparison of Fig. 3 and Fig. 7 it can be seen that the rates of appearance of the two thiopurine drugs in the serosal secretions are similar at 1 mmol/l (Table 1) . When the serosal appearance of unmetabolized drug plus 6-thiouric acid is compared (Fig. 5 and Fig. 8 ) the rates of appearance are virtually identical, suggesting a similar passive entry process for the two drugs.
The two drugs are transported at similar rates despite the fact that 6-mercaptopurine reduces the rate of water transport by 30%. The observation that glucose transport is inhibited to a greater extent than water transport suggests that 6-mercaptopurine inhibits water transport through its inhibition of glucose transport. Since 6-thioguanine has no effect on the rate of transport of water or glucose, the effects of 6-mercaptopurine seem to be dependent on the characteristics of the thiol group in this compound. Table 1 . Rates of thiopurine appearance in the serosal secretions Values are regression coefficients calculated for perfusion times from 50 to 100 min from all the points at each 10 min time intervalkthe standard error of the regression; n=number of perfusions. The results reported in this paper indicate that it is important to consider the intestinal metabolism of both thiopurine drugs when they are administered orally. Although the use of xanthine oxidase inhibitors prevents conversion of the thiopurines to 6-thiouric acid, allopurino1 will be of limited value in man because it is metabolized to oxypurinol [6] , which inhibits thiopurine transport. Finally, it should be noted that in the mouse the absorption of glucose and water are adversely affected by 6-mercaptopurine but not by 6-thioguanine.
